Genetic counselling in presymptomatic individuals with a family history of myotonic dystrophy (DM) is problematic. A genetic test to identify the presymptomatic carrier of the gene for DM would therefore be advantageous. We report studies comparing ophthalmic examination with a genetic test based on DNA linkage studies in nine DM families. The genetic test involved the use of five probes from four loci linked to the DM locus. Some discrepancies between ophthalmic and genetic tests were observed. Genetic counselling following prediction of genetic status was possible for 18 out of 20 patients from seven out of nine families.
Myotonic dystrophy (DM) is an autosomal dominant disorder in which the basic gene defect is still unknown. The gene causing DM poses special problems because of the extreme clinical variability of its expression. Many tissues can be affected with variable degrees of severity and the onset of clinical symptoms can occur at any age. Once symp toms have developed, pulmonary and cardiac complications may lead to premature death. The most common ocular abnormalities in patients with DM are lenticular changes, which may be presymptomatic, leading to cat aract formation. Varying types of lenticular changes, demonstrated to be present in all symptomatic patients,1.2 have been described as iridescent dust like opacities/ small snow ball like opacities and posterior subcapsular plaques.l The present consensus view is that exclusion of an individual from gene carrier status may not be possible until after the age of 40 years4 on the basis of ophthalmic and neurological examination.
Genetic counselling is a major problem in all DM families because identification of the presymptomatic individuals who carry the gene, which can then be passed on to 50% of their offspring, is clinically difficult. It is further complicated in heterozygous women since of the 50% conceptions which will carry the DM gene, 12% will not come to term, 9% will result in a child with congenital DM and 29% will develop symptoms in later life. 4 In DM families, where age of onset of symptoms is late, decisions relating to childbearing may well have been made before the genetic status of the prospective parent can be determined.
Because of the difficulty in identifying pre symptomatic individuals many clinical mark ers other than examination of the lens have been investigated and evaluated for their abil ity to predict heterozygous status, including electromyography,S skull X-ray,6 serum insulin7 and immunoglobulin analysis.H Other workers9•IO have identified polymorphic bio chemical markers (ABH secretory blood group, the complement component 3 locus (protein C3» which may be inherited together with the DM gene and which have been assigned to chromosome 19.11 Such markers are said to be linked to the DM gene and can be used to track the gene within fam ilies. More recently, several polymorphic DNA markers, derived from the gene for apolipoprotein cn (ApoClI), 12 have been identified which are more closely linked to DM than the protein C3 linkage group. The development of these polymorphic DNA markers as a genetic test for the presympto matic carrier of the gene for DM was rapidly reported. 13 The introduction of further probes helped to solve the problem of the uninfor mative family and resulted in the genetic test being available for many DM families. 14 How ever, problems are encountered with the test because the clinical assignment of the highly variable DM phenotype is still required within each family. Because ophthalmologists are usually involved in the clinical assignment of DM status and thereby in genetic counselling of families with DM, we designed this study to examine the current relationship between ophthalmic assessment and DNA probe studies.
We report both the clinical findings and the results of studies with ApoClI and more recent DNA probes in nine families with well characterised myotonic dystrophy. Prediction of genetic status followed by genetic coun selling was possible in seven out of nine families.
Materi a ls a nd methods

Clinical and family studies
Nine families had specifically requested defi nition of genetic status as soon as DNA tests became available. Family members who were without overt clinical signs of DM were referred for full ophthalmic examination. Flu orescein angiography and electrophysiology were not routinely carried out. Most patients were examined by one observer; four patients were seen elsewhere. In addition all patients had a neuromuscular examination and electromyography was performed in a few cases before clinical status for DM was assigned. Families 2,3, 4 and 5 all had an original gener ation with an obligate heterozygote where the disease had not been diagnosed. Family 6 starts with siblings with cataracts.
Within the nine families there are 15 living affected women, with an average age of 39 years. Six of these women have not yet had any children although they are of childbearing age; four have a poor obstetric history, includ ing early pregnancy loss and three dead and one living congenital DM children; five reported no problems in pregnancy. There are 25 affected males in these pedigrees, 12 of whom are dead. Four of the affected males are congenital cases of DM; ten of the men have had families and eleven are childless; of this childless group, six were diagnosed before the age of 20 years and the other five have an average age of 41 years.
The nine families contain 20 enquiring adults. Eighteen of this group have a one in two a priori risk of carrying the gene. Tw elve are under 40 years of age, with an average age of 28 years; the other six have an average age of 46 years. These 18 enquiring adults had 19 offspring, 14 of whom were under 18 years of age, dependent on their results. The other two enquiring adults were affected individuals seeking prenatal tests.
Finally amongst the nine families, there are a further seven offspring of four affected indi viduals with an a priori risk of one in two of carrying the gene; five of these are under 18 years of age, the other two are the adult off spring of a newly diagnosed case.
Laboratory studies
DNA samples were extracted from peripheral blood lymphocytes from 69 individuals. Table  I lists the five probes from four DNA loci linked to DM on chromosome 19 which were used in this study. Between them they identi fied nine sets of polymorphic markers charac terised by the length of the DNA fragment cut by the appropriate restriction enzyme. These markers are known as Restriction Fragment Length Polymorphisms (RFLP). Restriction enzyme digests 3 f-lg DNA per sample were carried out according to the manufacturers instructions, separated on a 1 % agarose gel by . 'We are grateful to these workers for their gift of probes.
electrophoresis and blotted onto Hybond-N filters. The probes were oligo labelled and hybridisation carried out for more than 16 hours at 65°C in the presence of 10% dextran sulphate. The filters were washed free of non specifically bound probe and an autoradio graph of the filter was made showing the poly morphic marker data.
Results
Linkage studies
Polymorphic markers from 69 individuals in nine families were analysed. The original work with the ApoCII probe demonstrated both the highly polymorphic nature of the Taq I RFLP and strong linkage disequilibrium20 between the markers of the ApoCII and the pSC 11 probes. Because of this, only three of the nine families were fully informative. The final results obtained with the full battery of probes resulted in seven fully informative families. Figure 1 shows the results of RFLP analysis in family 6, from which the markers which are tracking with the DM gene can be identified. We observed one recombinant event which was between ApoCII and CKM 3' in family 1.
Analysis of pedigrees Table II shows the nine families compared across the generations. In generation I, the probes identified the putative obligate hetero zygote in families 2,3, 4 and 5. In generations II and III the numbers of affected individuals together with their mean age is given; the enquiring adults are identified within their generation. All families show a reduction in the mean age of diagnosis with successive generations. Haplotype separated by I are phase derived .
Analysis of Individual results
• identifies the best informative marker in this family. have been described. 1 Slit lamp biomicro scopy of the lens for early characteristic opac ities is routinely undertaken as a marker of carrier status in the presymptomatic patient. Because lens opacities occur presymptomati cally,5.22 patients are frequently referred for ophthalmic assessment during genetic coun- unaffected uninformative tomatic DM in any particular pedigree. The present consensus is that exclusion of the indi vidual from gene carrier status may not be possible until after the age of 40 years. 4 Because of the difficulty of identifying the presymptomatic carrier of the DM gene, the prospect of a more sensitive test utilising DNA linkage studies was appealing. How ever, this type of linkage study is only useful if the DNA marker is close to the disease gene, because crossing over (recombination) occurs between the chromosomes at meiosis at a rate dependant on the distance between the marker and the gene. The effect of recombi nation is to introduce an error into the linkage analysis whereby the disease gene is no longer tracking with the original marker.
These studies were initiated in order to give genetic counselling to 20 enquiring adults from nine families. With one exception, the families were known to us before the DNA tests were undertaken and the prospect of such tests becoming available had been discussed with the 'families over the last two to three years. The initial screening of nine families known to our Clinical Genetics Service with the Apoell probe was disappointing. The DNA markers were highly polymorphic making it difficult to track the gene within the family and the mark ers themselves tended to track together (link age disequilibrium). Since we could not resolve carrier status using the DNA probes we still had to rely on clinical examination in six families. The introduction of newer probes resolved this problem.
Of our group of 20 enquiring adults, two were clinically affected women who were plan ning to have a prenatal diagnosis as a result of the DNA tests; neither has yet made such a request. Thirteen patients were clinically unaffected and informative DNA tests indicated that they did not carry the DNA marker tracking with the D M gene in their family. They were therefore given a low probability of between 2-5%, dependent on the particular informative marker, of carrying the gene for DM. These individual results indicate the difficul ties encountered in providing presymptomatic tests in DM families. The first problem is to interpret the lens examination with reference to the age of the patient. Ta ble II which summar ises some of the family data, clearly demon strates the simple assertion that the age of affected individuals decreases through the gen erations. This controversial phenomenon, which had been referred to as anticipation, was formerly ascribed to a statistical artefact of biased data gathering.24 Recent work25 strongly suggests that anticipation may be inherent in the transmission of the disease, which has important practical consequences for genetic counselling. It would therefore appear that the lens examination needs to be referred to the age of the patient and to the particular family under study, with the advice of Harper4 forming a general guideline. This present study demon strates some of the limitations of lens examin ation in the presymptomatic detection of DM. However the study also highlights the continu ing necessity for good ophthalmic examination together with neurological assessment in all DM families and is particularly important in families where DNA tests are uninformative.
DNA tests should give a much more accurate assessment of the presymptomatic status of the individual. They also have their own error due to recombination and, since the markers must be assigned in each family, they remain firmly based on the clinical definition of an affected phenotype. The problem of recombination will be much reduced when probe markers which flank the gene are available. The p roblem will only be fully resolved when the gene for DM can be located and the abnormal sequence described.
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